Vitamins & Supplements

Allithiamine vs benfotiamine: which B1 wins for the gut?

February 5, 2025 · Rick Pescatore, DO
Allithiamine vs benfotiamine: which B1 wins for the gut?

Standard vitamin B1 cannot reach the tissues that need it most. The nerves running through your gut, the cells in your brainstem that handle nausea, the central wiring that decides whether a normal sensation lands as comfort or pain. All of it sits behind fatty cell membranes that water-soluble B1 struggles to cross. Two fat-soluble derivatives solve that problem in different ways. Both are honest options. Neither is a magic bullet.

TL;DR
Allithiamine crosses cell membranes faster and lands in nerve tissue. Benfotiamine is gentler on the stomach and accumulates over time. We use both, in different formulas.

Why standard thiamine fails for nerve targets

The vitamin B1 you find on most shelves is thiamine hydrochloride. It is water-soluble, which sounds like a feature but is the entire problem. Your gut absorbs it through a saturable transporter. Once that transporter is full, the rest passes through and ends up in the toilet.

Even the small fraction that makes it into circulation runs into a second wall. Cell membranes are fatty. Water-soluble molecules need a chaperone to get across, and thiamine does not have one in the doses most people take. So the B1 floating in your blood does not reliably reach the nerves in your gut wall, the vagal pathways tying gut to brain, or the deeper brain regions that govern nausea and central sensitization.

For someone with mild deficiency and a healthy gut, thiamine HCl is enough. For anyone targeting nerve tissue, the gut-brain axis, or the central wiring behind disorders of gut-brain interaction (DGBI), it routinely is not.

What makes a B1 derivative fat-soluble

Chemists figured out decades ago that if you bolt a fat-loving side chain onto the thiamine molecule, the whole thing slips through cell membranes without a transporter. Inside the cell, your own enzymes snap the side chain off and release active thiamine where it can do work.

Allithiamine and benfotiamine are both versions of this trick. They are not the same molecule. They are not even close cousins. They take different chemical paths to solve the same problem, and the path each takes changes where the B1 ends up.

Allithiamine: the garlic-derived nerve targeter

Allithiamine was identified in the early 1950s by Japanese researchers studying why people who ate raw garlic seemed to absorb B1 better than their diet predicted (Fujiwara, 1954). Garlic contains a sulfur compound, allicin, that reacts with thiamine to form a fat-soluble version that diffuses straight through cell membranes.

What makes allithiamine clinically interesting is where it lands. Animal and human work, much of it championed by Derrick Lonsdale over four decades of clinical practice, shows that allithiamine reaches nerve tissue and crosses the blood-brain barrier in ways water-soluble forms do not. Lonsdale's case series in functional dysautonomia, gut-brain dysregulation, and unexplained nausea built the practical clinical record we have today.

The catch: allithiamine has a sulfur signature that some people taste or smell, and it absorbs fast. That makes it powerful for central and nerve-level work and slightly less forgiving on an empty stomach.

Benfotiamine: the slow, steady accumulator

Benfotiamine took a different path. It was developed in Japan in the 1960s as a stable, well-tolerated lipid-soluble B1 designed for long-term oral use. Instead of a sulfur bridge, it uses an S-acyl chain that gets cleaved in the intestinal wall. The active thiamine then enters circulation gradually.

The strongest evidence base sits in diabetic peripheral neuropathy. The BENDIP trial (Stracke et al, 2008) tested benfotiamine in patients with painful diabetic neuropathy and showed meaningful symptom reduction over weeks of dosing, with a clean tolerability profile. Subsequent work has examined benfotiamine in early Alzheimer's, alcohol-related cognitive decline, and chronic inflammatory states, with consistent safety findings even at high doses.

Benfotiamine is gentle. It does not have the sulfur taste. It accumulates with daily use rather than spiking. The tradeoff is that it does not reach central nervous tissue as efficiently as allithiamine. Most of its action stays in peripheral nerves and the gut wall itself.

Side by side

Allithiamine Benfotiamine
Source Derived from garlic chemistry (allicin + thiamine) Synthetic S-acyl derivative
Solubility Fat-soluble, fast diffusion Fat-soluble, slow release
GI tolerance Strong; can have sulfur taste Very gentle, neutral taste
Blood-brain barrier Crosses readily Limited central penetration
Typical dose range 50 to 150 mg daily 150 to 600 mg daily
Evidence base Smaller body of work; strong clinical case series (Lonsdale) Larger RCT base in diabetic neuropathy (Stracke and others)

How to pick between them

The question is not which one is better. It is which one matches the job you are asking it to do.

If the target is central: brain fog, nausea anchored in central wiring, sensory amplification, the cluster of symptoms that comes with sensitized gut-brain pathways, allithiamine has the better case. It gets where it needs to go, and it gets there fast. That is why it sits in Clear, where the goal is reaching central machinery.

If the target is steadier, more peripheral, more about long-term tolerability and accumulation in nerve tissue and the gut wall itself, benfotiamine is the cleaner choice. Less likely to cause any GI noise. Easier to take daily for months. That logic shapes Calm, where the formulation aim is sustained support rather than acute central effect.

Some people do well with both, used for different reasons at different times. That is not hedging. That is matching the tool to the tissue.

Dosing reality

Neither form is a high-dose stunt. The evidence base for benfotiamine in neuropathy used doses in the 300 to 600 mg range. Clinical work with allithiamine has generally landed between 50 and 150 mg, sometimes higher for short courses under physician supervision. Most consumer products sit at the lower end of these ranges, which is reasonable for daily use.

Time of day matters less than consistency. Both forms get into tissue over weeks, not hours. People often expect a fast hit and stop too early. Give either form four to eight weeks before deciding whether it is doing anything for you.

What to do

  1. Read the label. If a product says vitamin B1 or thiamine HCl, it is the water-soluble form. That is not what you want if you are targeting nerve tissue or the gut-brain axis.
  2. Match the form to the goal. Central symptoms and gut-brain wiring lean allithiamine. Peripheral nerve support and long-haul daily use lean benfotiamine.
  3. Be patient. Four to eight weeks is a fair trial. Daily, with food, same time each day.
  4. Talk to your physician if you are managing a specific diagnosis, are pregnant, or are on prescription therapy. Lipid-soluble B1 is broadly well tolerated, but your doctor should know what you are taking.
  5. Pay attention to the response. Track sleep, bowel pattern, energy, and the symptoms you are actually trying to move. If nothing changes by week eight, change the variable.

Vitamin B1 is not glamorous. It is foundational. Get the form right and it does its job.